|
|
|
|
|
|
|
The 2026 European Association of Urology (EAU) Annual Meeting
|
|
|
|
|
| Closing the Knowledge Gap to Inform Policy Decision-Making: Health-Related Quality of Life and Health Anxiety in Men Undergoing Screening for Prostate Cancer
|
| Shuang Hao, PhD, MPH, MSc, BSc
|
| This MRI-based prostate cancer screening study found only modest, clinically small changes in health-related quality of life and health anxiety across the screening pathway, even among men undergoing blood tests, MRI, and biopsy. Health anxiety increased slightly—especially in men with positive tests—but generally stayed within the no or mild anxiety range, and the derived utility values and willingness-to-pay estimates help fill a key evidence gap needed for future cost‑effectiveness analyses and screening policy decisions.
|
|
|
|
|
|
| PFS Following Primary Staging with 18F-PSMA-1007 PET/CT Versus 18F-NaF PET/CT in Prostate Cancer: : Results from the PRISMA-PET Randomized Controlled Trial
|
| Karen Buch-Olsen, MD
|
| The PRISMA-PET randomized trial found that primary staging with 18F‑PSMA‑1007‑PET/CT changed both disease stage and downstream treatment allocation compared with 18NaF‑PET/CT in newly diagnosed high‑risk/unfavorable intermediate‑risk prostate cancer. Progression‑free survival was not significantly different overall, but there was a late-emerging trend toward longer PFS in high‑risk patients staged with 18F‑PSMA‑1007‑PET/CT, suggesting a possible longer‑term benefit that needs further follow‑up.
|
|
|
|
|
|
| Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: 10 years of follow up - Oncological Outcomes from a Randomized Phase 3 Trial
|
| Matheus Ruggeri, MD
|
| This 10-year randomized phase 3 trial found no overall oncologic benefit of extended versus limited pelvic lymph node dissection for unselected intermediate- and high-risk prostate cancer undergoing radical prostatectomy. However, in men with biopsy ISUP grade group 3–5, extended dissection significantly improved biochemical recurrence-free and metastasis-free survival, supporting extended pelvic lymphadenectomy as the preferred approach in this higher-grade subgroup.
|
|
|
|
|
|
| CAPTAIN: Randomized Controlled Trial Evaluating MRI-Guided TULSA Versus Robotic Prostatectomy – Initial Perioperative Outcomes
|
| Laurence H. Klotz, MD, FRCSC
|
| CAPTAIN is the first fully enrolled phase 3 multicenter randomized trial directly comparing MRI-guided TULSA to robotic prostatectomy for intermediate‑risk localized prostate cancer. Early perioperative data show that TULSA offers markedly less blood loss, no overnight hospital stay, faster return to usual activities and work, and significantly better 6‑month preservation of both urinary continence and erections, while longer-term oncologic control will be reported after extended follow‑up.
|
|
|
|
|
|
|
|
|
|
|
| Optimizing the Timing of Docetaxel After Androgen Receptor Pathway Inhibitor Therapy: Development and Validation of a Novel Prognostic Model in mCRPC
|
| Rodrigo España Navarro, MD
|
| This work developed and externally validated a six-variable prognostic model to estimate progression-free and overall survival with docetaxel after an androgen receptor pathway inhibitor in mCRPC. By incorporating both baseline factors and dynamic features of prior ARPI response, the tool stratifies patients into low- and high-risk groups with reasonable discrimination, helping clinicians individualize whether—and how urgently—to proceed with docetaxel in this setting.
|
|
|
|
|
|
| ARTO Trial: Long-Term Overall Survival Analysis from a Randomized Phase II Trial Testing the Benefit of SBRT Addition to Abiraterone in Oligometastatic CRPC Patients
|
| Giulio Francolini, MD
|
| This randomized phase II ARTO trial showed that adding stereotactic body radiotherapy to abiraterone + ADT in first‑line oligometastatic CRPC significantly prolonged biochemical and radiologic progression‑free survival and improved overall and prostate cancer–specific survival, without new safety concerns. These durable survival gains support metastasis‑directed SBRT on top of systemic therapy in carefully selected oligometastatic CRPC patients, while phase III confirmation is still needed.
|
|
|
|
|
|
| Time-Dependent Survival Benefit of Enzalutamide + Radium-223 in mCRPC: Reconstructed Analysis of the PEACE-3 Trial
|
| Wei Chen
|
| This reconstructed PEACE-3 analysis shows that adding radium‑223 to enzalutamide in bone‑metastatic mCRPC yields a delayed but substantial overall survival benefit that only becomes statistically significant after about 5 years, growing to >6 months gain and an ~80% relative reduction in death risk by 72 months. There is no survival advantage—and some early excess toxicity‑related deaths—during the first 18 months, so this combo is best suited to patients with good prognosis and sufficient life expectancy, and its benefit is properly appreciated only with time‑dependent, non‑proportional hazards analyses rather than standard Cox models.
|
|
|
|
|
|
| External Validation of a Prognostic Risk Model for Overall Survival After Radium-223 Treatment in mCRPC
|
| Naoki Fujita, MD, PhD
|
| This large external validation study confirmed that three simple factors—extent of disease >1, PSA >10 ng/mL at radium-223 start, and not completing all 6 cycles—are each independently associated with significantly worse overall survival in mCRPC patients treated with radium-223. Stratifying 794 men by how many of these risk features they had produced clearly separated survival curves and showed good discrimination for 2- and 3-year survival, supporting this model as a practical tool to identify which patients are most—and least—likely to benefit from radium-223.
|
|
|
|
|
|
| Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in mCRPC: A Multicenter Retrospective Analysis in Japan
|
| Takuma Kato, MD, PhD
|
| Takuma Kato presents a large Japanese multicenter retrospective study which found that combining radium‑223 with enzalutamide in mCRPC was generally well tolerated, with low rates of grade ≥3 hematologic and non‑hematologic toxicities and no treatment‑related deaths. Use of bone‑modifying agents emerged as critical: their absence tripled the risk of symptomatic skeletal events, while radium‑223 + enzalutamide modestly prolonged time to progression without clearly changing overall survival, reinforcing the need for routine bone protection when using this combination.
|
|
|
|
|
|
|
|
|
|
|
